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Summary 28 
The skin is equipped with specialized mechanoreceptors that allow the perception of the 29 
slightest brush. Indeed some mechanoreceptors can detect even nanometer-scale movements. 30 
Movement is transformed into electrical signals via the gating of mechanically-activated ion 31 
channels at sensory endings in the skin. The sensitivity of Piezo mechanically-gated ion 32 
channels are controlled by stomatin-like protein-3 (STOML3), which is required for normal 33 
mechanoreceptor function. Here we identify small molecule inhibitors of STOML3 34 
oligomerization that reversibly reduce the sensitivity of mechanically-gated currents in 35 
sensory neurons and silence mechanoreceptors in vivo. STOML3 inhibitors in the skin also 36 
reversibly attenuate fine touch perception in normal mice. Under pathophysiological 37 
conditions following nerve injury or diabetic neuropathy the slightest touch can produce pain, 38 
and here STOML3 inhibitors can reverse mechanical hypersensitivity. Thus, small molecules 39 
applied locally to the skin can be used to modulate touch and may represent peripherally 40 
available drugs to treat tactile-driven pain following neuropathy. 41 
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56 
Introduction 57 
All skin sensation starts with the transformation of a physical stimulus into an electrical 58 
signal called a receptor potential. The receptor potential is encoded as action potentials (AP), 59 
which convey information to the brain to initiate perception1. Currently pharmacological 60 
agents that modulate the first step in the transformation of light touch stimuli into an 61 
electrical signal, a process called sensory mechanotransduction, are not available. The 62 
mechanosensitive ion channel Piezo2 and its modulator STOML32 have both been shown to 63 
be necessary for mechanoreceptors to transduce light touch3–6. Paradoxically, under 64 
pathophysiological conditions, intense pain can also be triggered by light touch7,8, for 65 
example after traumatic nerve injury9. Nerve injury induced touch-evoked pain was found to 66 
be largely absent in Stoml3-/- mutant mice6. STOML3 is an endogenous regulator of the 67 
sensitivity of mechanosensitive ion channels like Piezo in sensory neurons and STOML3 68 
self-association appears to be necessary for this function10,11. Interestingly, Piezo2 has an 69 
essential role in human proprioception and touch sensation12,13. Therefore we set out to 70 
discover and test whether small molecules that can disrupt STOML3 self-association can be 71 
used to modulate touch under normal and pathophysiological conditions.  72 
Identification of small molecule STOML3 inhibitors 73 
In mammals STOML3 belongs to a family of five structurally conserved membrane proteins, 74 
including Stomatin, STOML1, STOML2, and Podocin10,14–18, all of which self-associate via 75 
their stomatin-domain (Supplementary Fig. S1a)10. Self-association of stomatin-domain 76 
proteins can be monitored in HEK293 cells using Bimolecular Fluorescence 77 
Complementation (BiFC) whereby N- and C-terminal halves of the YFP molecule are tagged 78 
to the prey and bait protein STOML32,19  (Fig. 1a). Irreversible association of the YFP 79 
fragments produces fluorescence that increases linearly over time (Fig. 1 b). Mutations in one 80 
STOML3 pair that disrupt oligomerization (V190P or LR89,90EE) significantly reduce the 81 
rate of signal development (Fig.  1b)2,10. We used this cellular assay in a high throughput 82 
format to screen for small molecules that significantly inhibit the BiFC signal, a measure of 83 
STOML3 self-association. In a primary screen of about 35000 small molecules (each at 20 84 
µM), obtained from the central compound collection of the Leibniz Institute for Molecular 85 
Pharmacology screening unit (www.chembionet.info), 21 molecules were found to 86 
reproducibly decrease STOML3 self-association based on the slope of YFP signal 87 
development. Of these 21 molecules 19 did not pass stringent control tests (see Materials and 88 
Methods). The two remaining inhibitory compounds were designated Oligomerization 89 
Blocker 1 and 2, (OB-1 and OB-2) (Fig. 1d,e). In further BiFC assays, the STOML3 90 
oligomerization blocker, OB-1 was an effective inhibitor of the self-association of Stomatin, 91 
STOML1, STOML2, but not Podocin (Supplementary Fig. 1a). Lower OB-1 concentrations 92 
(2 µM) also inhibited the BiFC signal (Supplementary Fig. 1b). The OB-1 molecule was also 93 
re-synthesized in house and exhibited the same activity in the BiFC assay as the 94 
commercially available sample. The human STOML3 peptide sequence is 92% identical to 95 
that of the mouse and 100% identical in the core stomatin-domain and human STOML3 also 96 
showed self-association (Fig. 1f). More importantly for potential future clinical development 97 
self-association of the human STOML3 protein was also inhibited by OB-1 (Fig 1f). 98 
STOML3 oligomerization dictates domain size in the plasma membrane 99 
We next asked if OB-1 and OB-2 modulation of STOML3 oligomerization state influences 100 
clustering of the protein in the plasma membrane. We used super-resolution dSTORM 101 
microscopy20–22 to visualize FLAG–tagged STOML3 at the plasma membrane of transfected 102 
N2a cells. Using dSTORM we could show that STOML3 was present in microdomains at the 103 
plasma membrane (Fig. 1g). The size of the STOML3 clusters was variable (full width at half 104 
maximum, FWHM = 24.6 ± 2.8 nm, mean ± sem, Fig. 1h.) but these domains may contain 105 
more than one STOML3 dimer10. Introduction of the V190P mutation disrupts 106 
oligomerization of STOML3 and abolishes its ability to modulate the mechanosensitivity of 107 
Piezo1 channels2. This STOML3 variant exhibited significantly smaller clusters in the plasma 108 
membrane (Fig. 1g,h), demonstrating that by disrupting STOML3 oligomerization we can 109 
manipulate and measure nanoscale changes in STOML3 cluster size. Pre-incubation of N2a 110 
cells expressing STOML3-FLAG with OB-1 or OB-2 for three hours led to significantly 111 
reduced STOML3-FLAG cluster sizes compared to vehicle treated cells (Fig. 1g,h). The 112 
effects of OB-1 did not produce changes in Stoml3 mRNA levels in these cells 113 
(Supplementary Fig. 2a). Thus we obtained independent support for the notion that OB-1 and 114 
OB-2 reduce STOML3 oligomerization state, an important consequence of which is a 115 
reduced STOML3 cluster size at the plasma membrane. 116 
STOML3 inhibitors modulate mechanotransduction currents 117 
Endogenously expressed STOML3 in N2a cells is required to maintain Piezo channel 118 
sensitivity to membrane deflection2. By precisely deflecting defined areas of the membrane-119 
substrate interface using a pillar array we could activate Piezo1 currents in N2a cells with 120 
displacements ranging from 100 - 1000 nm (Fig. 2a,b). Both OB-1 and OB-2 reduced the 121 
sensitivity of mechanosensitive currents to pillar deflection (Fig. 2b). Pre-incubation of cells 122 
with OB-1 for periods of between 1 and 3 h reduced Piezo1 current amplitudes, but the effect 123 
was only maximal after 3 h (Supplementary Fig. 2b). Recording mechanically-activated 124 
currents in the presence of different concentrations of OB-1 revealed a steep concentration 125 
dependence with a calculated IC50 of 10 nM, Hill coefficient 0.6 (Fig. 2c). 126 
Next we evaluated the effects of OB-1 and OB-2 on mechanosensitive currents in acutely 127 
cultured mouse sensory neurons. Neurons were classified on the basis of their AP 128 
configuration as mechanoreceptors or nociceptors2,23. We found that mechanically gated 129 
currents in mechanoreceptors start to activate with membrane deflections of < 50 nm2, but 130 
this sensitivity was substantially reduced after exposure to OB-1 or OB-2 (Fig. 2 d,e). Thus 131 
significant mechanically gated currents were only observed in OB-1 or OB-2 treated cells 132 
with deflections that exceeded 100 nm. The threshold for activation of mechanosensitive 133 
currents in nociceptive sensory neurons is normally higher than that of mechanoreceptors2 a 134 
finding reproduced here (Fig. 2e,f). However, we also observed that OB-1 or OB-2 treatment 135 
produced a significant reduction in the amplitude of mechanically gated currents in 136 
nociceptors with stimulus magnitudes between 100 and 500 nm (Fig. 2f). In addition the 137 
latency for mechanically gated currents as well as the activation time constant for current 138 
activation τ1 was significantly slowed in nociceptors after treatment with OB-2 139 
(Supplementary Fig. 2 c,d). The exposure of N2a cells or sensory neurons to OB-1 for 3h did 140 
not lead to any changes in the level of Stoml3 transcripts (Supplementary Fig. 2a), suggesting 141 
that our molecules change gene expression, or transcript stability. Cell soma indentation can 142 
also be used to evoke so called Rapidly-adapting currents (RA-currents, inactivation constant 143 
τ2 < 5 ms) in mechanoreceptor sensory neurons23,24 and after exposure to OB-1 ~ 60% of the 144 
neurons (12/21 neurons) displayed no mechanosensitive current compared to control or 145 
vehicle treated neurons (21%, 8/38 neurons), this effect was statistically significant (Fisher’s 146 
exact test p < 0.01 Supplementary Fig. 3a-e). Neither of the two compounds tested had any 147 
discernable effects on voltage-gated currents or membrane excitability as evidenced by the 148 
fact that APs were of normal amplitude and shape after treatment (Fig. 2h,i). For example, 149 
cultured sensory neurons treated for at least 3 h with 20 µM OB-1 displayed no alteration in a 150 
number of parameters indicative of electrical excitability (Fig 2g-i, Supplementary Table 1). 151 
In summary, using two independent assays we found that OB-1 is a powerful inhibitor of 152 
native mechanosensitive currents. Stomatin-domain proteins can also negatively regulate 153 
members of the acid sensing ion channel family (ASICs) in a subunit-specific manner 154 
6,10,25,26. However, OB-1 had no detectable effect on the negative modulation of ASIC3 155 
mediated currents by mouse Stomatin (Supplementary Fig. 4).  156 
A STOML3 inhibitor can silence touch receptors 157 
Many cutaneous mechanoreceptors in Stoml3-/- mice innervate the skin, but cannot be 158 
activated by mechanical stimulation5,6. We made subcutaneous injections of the OB-1 159 
compound (250 - 500 pmol per paw) into the mouse hairy skin innervated by the saphenous 160 
nerve and recorded from sensory afferents 3 h later using an ex vivo skin - nerve 161 
preparation5,27. In wild type mice the vast majority of myelinated and unmyelinated fibers are 162 
mechanosensitive4–6, demonstrated by tracing the spike evoked by local electrical stimulation 163 
of nerve branches and then searching for the nearby mechanosensitive receptive field (Fig. 164 
3a). In contrast, in skin pre-treated with OB-1 over 39% of Aβ-fibers (19/44) lacked a 165 
mechanosensitive receptive field, and this was significantly different from vehicle-injected 166 
controls where less than 7% (5/69 fibers) were found to be insensitive to mechanical stimuli, 167 
p < 0.001 Fischer’s exact test (Fig. 3a,  Supplementary Table 2). An almost identical 168 
proportion of OB-1 treated Aβ-fibers were insensitive to mechanical stimuli in female mice 169 
as in male mice (Fig. 3a). Amongst the Aδ-fibers we also observed an increase in the 170 
proportion of fibers for which no mechanosensitive receptive field could be found (21%, 8/38 171 
fibers compared to 6%, 1/19 fibers in controls, but this was not significantly different; 172 
Fischer’s exact test, p > 0.24). There was also no change in the proportion of C-fibers that 173 
lack a mechanosensitive receptive field (Fig. 3a). We next examined the physiological 174 
properties of the remaining mechanosensitive afferents in OB-1 treated skin. However, the 175 
proportion of mechanoreceptor types found, as well as the mechanosensitivity of the 176 
remaining Aβ-fiber mechanoreceptors (Rapidly and Slowly adapting mechanoreceptors, 177 
RAMs and SAMs) was unchanged compared to controls (Supplementary Fig. 5a-e). The 178 
mechanoreceptor silencing effect of local OB-1 treatment was completely reversible as 179 
recordings from afferents 24 h after treatment revealed no significant loss of 180 
mechanosensitivity, also compared to vehicle treated skin (Fig. 3a). Thus, a STOML3 181 
oligomerization inhibitor can specifically and reversibly silence touch receptor activity 182 
without changing axonal excitability. 183 
Although, we found no evidence that C-fiber nociceptors are silenced by OB-1 treatment 184 
(Fig. 3a) we did note a statistically significant effect of local OB-1 treatment on the 185 
mechanosensitivity of C-fiber afferents that respond to both thermal and mechanical stimuli 186 
(C-mechanoheat fibers, C-MH, Two-way ANOVA, p < 0.05) (Fig. 3b). C-mechanoheat 187 
fibers also displayed significantly elevated mechanical thresholds for activation that were on 188 
average almost twice that of control fibers (196.5 ± 35.6 mN, mean ± sem in OB-1 treated 189 
skin vs 106.9 ± 17.4 mN, mean ± sem in vehicle treated skin, Mann-Whitney U test, p < 0.05) 190 
as measured using a force measurement system attached to the stimulus probe (Fig. 3c). The 191 
firing rates of C-mechanonociceptors (C-Ms) that lack heat sensitivity, to suprathreshold 192 
mechanical stimuli were not significantly attenuated in OB-1 treated skin (Fig. 3d,e).  193 
Touch perception is attenuated by local OB-1 treatment 194 
We used a tactile perception task in head-restrained mice to assess the effects of OB-1 on 195 
touch sensation. Water-restricted mice were trained to press a sensor with their forepaw 196 
within 500 ms after the onset of a 30 ms cosine mechanical stimulus applied to the same paw. 197 
Correct responses were rewarded with water. Mice learned this task to a high degree of 198 
reliability after a 7-10 day training period (Fig. 4a). Different stimulus amplitudes were then 199 
used to determine a psychometric curve for each mouse (Fig. 4a,b). We next injected the drug 200 
vehicle solution into the forepaw and obtained a new psychometric curve for each mouse 3 - 201 
5 h later. On the next day, the forepaw was injected with the OB-1 compound (11 nmol per 202 
paw) followed by behavioral testing. At least 24 h after the OB-1 testing day, the recovery 203 
behavior was tested without any prior injection. Following OB-1 treatment the psychometric 204 
curve was shifted to the right for stimulus strengths between 125-275 µm indicating less 205 
reliable stimulus detection (Wilcoxon Signed Rank Test, vehicle vs OB-1, p = 0.026; OB-1 vs 206 
recovery, p = 0.0043) (Fig. 4 b,c). Vehicle treatment produced no significant change in the 207 
psychometric curve (Wilcoxon Signed Rank Test, control vs vehicle p = 0.30). The detection 208 
rates of threshold stimuli returned to pre-treatment levels 1-4 d after treatment (Wilcoxon 209 
Signed Rank Test, vehicle vs recovery, p = 0.12). These data indicate that silencing of a 210 
subset of mechanoreceptors via STOML3 inhibition is sufficient to reduce the reliability of 211 
near threshold touch perception in mice. 212 
Peripheral STOML3 blockade reverses tactile allodynia 213 
Neuropathic pain is a debilitating condition in which intense pain can be initiated by merely 214 
brushing the skin, activating low-threshold mechanoreceptors7–9,28,29. We used the chronic 215 
constriction injury model (CCI), which involves direct damage to sciatic nerve axons 216 
(Supplementary Fig. 6a-f) that innervate the hypersensitive plantar hindpaw skin. Baseline 217 
paw withdrawal thresholds in wild type and Stoml3-/- mice did not differ, as measured with 218 
von Frey hairs using an adapted up-down method30 (Fig. 5a). However, after induction of a 219 
unilateral CCI9, paw withdrawal thresholds dropped profoundly in wild type mice but were 220 
only moderately reduced in Stoml3-/- mice, Two-way ANOVA, p < 0.001 (Fig. 5a). Thermal 221 
hyperalgesia also accompanies neuropathic injury7,9,31, a phenomenon that we also observed. 222 
However, the heat hyperalgesia observed in Stoml3-/- mice was identical to that in wild type 223 
controls (Fig. 5b).  224 
We next asked whether local application of OB-1 can ameliorate tactile-evoked pain behavior 225 
in neuropathic models. We found no change in paw withdrawal thresholds to mechanical 226 
stimuli in the paws of naïve mice treated with an intraplantar dose of OB-1 (250 - 500 pmol 227 
per paw) (Fig. 5c). However, when we applied an intraplantar dose of OB-1 to the paws of 228 
wild type mice with established neuropathic pain (CCI model 6 - 21 days after induction) we 229 
observed a complete reversal of the tactile-evoked pain or allodynia, 0.15 ± 0.06 g (CCI) vs 230 
0.7125 ± 0.12 g (OB-1 treated p = 0.0028; paired t-test (Fig. 5d). The effects of OB1 were 231 
also indistinguishable on female and male mice with CCI (Fig 5d)32. We also applied OB-1 to 232 
the contralateral paw at the same concentration that was effective at reversing allodynia 233 
present in the paw ipsilateral to the injury, but observed no reversal of established 234 
hypersensitivity (Fig 5e). These results suggest that the actions of OB-1 in reversing 235 
hypersensitivity are due to inhibition of sensory neuron mechanotransduction in the skin and 236 
not to systemic or central actions. The reversal of tactile allodynia observed with local OB-1 237 
treatment was indistinguishable from that found with systemic gabapentin treatment (Fig. 5f), 238 
a standard, centrally acting drug, in clinical use for the treatment of neuropathic pain 33. 239 
Using a series of OB-1 concentrations we could determine a half-maximal effective dose 240 
(ED50) of 4.42 µM (or approximately 20 pmol per paw) (Fig. 5g). The effects of a single OB-241 
1 dose became maximal 3 h after the injections and wore off slowly over the next 12 h so that 242 
the effect was absent after 24 h (Fig. 5h). To test the idea that OB-1 reverses mechanical 243 
hypersensitivity primarily by inhibiting STOML3 oligomerization we tested the effects of 244 
local OB-1 on the mechanical sensitivity of Stoml3-/- mice with CCI. Mechanical 245 
hypersensitivity following CCI is much less prominent in Stoml3-/- mice (Fig. 5a,i) but we 246 
observed no change in paw withdrawal threshold after treatment of neuropathic paws of 247 
Stoml3-/- mice with OB-1 (Fig. 5i). Off-target effects are an issue for any biologically active 248 
small molecule. We therefore tested the effects of 20µM OB-1 in a commercially available in 249 
vitro pharmacology panel (www.cerep.fr) consisting of 79 receptors and ion channels (see 250 
Supplementary Dataset 1). Significant inhibition of specific ligand binding to the selected 251 
receptors was seen in a few cases (6/79), but there is at present no data implicating any of 252 
these receptors in peripheral nociception. The agreement between the in vitro and in vivo 253 
effects of STOML3 inhibition and the results of genetic ablation of the Stoml3 in the mouse 254 
suggest that OB-1 exerts its biological effects primarily on STOML3. The remarkable 255 
protection from touch-evoked pain in animals lacking STOML3 led us to hypothesize that the 256 
nerve injury may itself lead to a change in the levels of Stoml3 mRNA expression in the 257 
DRG. Up-regulation of STOML3 could in turn exacerbate touch-evoked pain by enhancing 258 
the sensitivity of mechanotransduction in injured sensory afferents. Using real-time 259 
quantitative PCR we measured a doubling in Stoml3 mRNA expression levels in the lumbar 260 
DRGs that project axons to the ligation site compared to the control uninjured side (p<0.01; 261 
Mann-Whitney U-test) (Fig. 5j).  262 
The CCI model involves direct damage to the axons that innervate the hypersensitive skin, in 263 
this case the plantar hindpaw34. Neuropathic touch hypersensitivity is also induced in the 264 
same skin area by cutting adjacent nerves to the tibial nerve that innervates the plantar foot 265 
35,36. Spared tibial nerve injury (SNI) mice develop a long lasting hypersensitivity of similar 266 
magnitude to that observed following CCI (Supplementary Fig. 7a). Administration of OB-1 267 
to the plantar skin in the SNI model produced no reversal of allodynia (Supplementary Figure 268 
7b). We removed the lumbar DRGs from these animals and found no change in the levels of 269 
Stoml3 mRNA between the injured and uninjured side in this model (Supplementary Fig.7c). 270 
This finding suggests that the effects of OB-1 in alleviating mechanical hypersensitivity may 271 
in part depend on whether STOML3 levels are up-regulated.  272 
Mechanical hyperalgesia is also a prominent feature in inflammatory pain, which is largely 273 
dependent on increased nerve growth factor (NGF) levels37. Systemic dosing with NGF (1 274 
mg/kg) is sufficient to provoke long-lasting mechanical and heat hyperalgesia37,38, which 275 
were both unchanged in NGF-injected Stoml3-/- mice (Supplementary Fig. 7d,e). 276 
Additionally, mechanical hypersensitivity after NGF was also not reversed by local 277 
intraplantar OB-1 (Supplementary Fig. 7f,g). This data is consistent with the prevailing view 278 
that NGF-dependent cutaneous mechanical hyperalgesia is primarily driven by central 279 
sensitization37,39.  280 
Regulation of Stoml3 mRNA and protein after injury 281 
The levels of Stoml3 mRNA are very low in the DRG and we have never found an antibody 282 
that is sensitive or specific enough to detect endogenous STOML3. We therefore generated 283 
two new knock-in mouse models to monitor in the first case Stoml3 gene expression and in 284 
the second case STOML3 protein. We created a knockin allele in which a β-galactosidase 285 
cassette with a nuclear localization signal (NLS) was fused in frame with the start codon of 286 
the Stoml3 gene (Stoml3lacZ mice) (Supplementary Fig. 8 a-c). This reporter allele allowed us 287 
to visualize subsets of sensory neurons that express Stoml3 (Fig. 6a). We observed lacZ 288 
staining in around half of sensory neurons with cell bodies > 20 µm in diameter, a population 289 
known to consist of mechanoreceptors (Fig. 6a). The number of lacZ-positive neurons more 290 
than doubled in the L6-L4 ganglia after a unilateral CCI challenge and the cells were 291 
predominantly > 20 µm in diameter, Fisher’s exact test, p < 0.0001 (Fig. 6b). This data is 292 
consistent with the idea that chronic nerve constriction leads to an increase in the number of 293 
large and medium sized sensory neurons that express higher levels of Stoml3. Consistent with 294 
our observation that Stoml3 mRNA levels are very low in the DRG, the LacZ-positive cells 295 
were difficult to visualize when screening for β-galactosidase activity and antibodies directed 296 
against the β-galactosidase protein did not give staining. It was therefore difficult to obtain  a 297 
neurochemical profile of Stoml3 expressing sensory neurons. 298 
In the second knock-in mouse we introduced nucleotides encoding the StrepII tag40  3’ to the 299 
start codon (Fig 6c, Supplementary Fig. 8d-f). The genomic fusion was successful as we 300 
could amplify Stoml3 mRNA transcripts containing the nucleotide sequence encoding an N-301 
terminally StrepII-tagged Stoml3. We carried out Western blotting for the StrepII-tagged 302 
protein in Stoml3StrepII CCI mice and extracted protein from sciatic nerve at day 2, day 6 and 303 
day 13 post-injury. We could detect a specific band (absent in Stoml3-/- nerve) of the 304 
appropriate molecular weight in protein extracts from the sciatic nerve, but only after using a 305 
strong denaturing buffer containing 8M urea (Fig 6d). We could sometimes detect the 306 
StrepII-STOML3 band from extracts made from DRG but this was much weaker and less 307 
reliable (data not shown). Notably, we found more intense -STOML3-StrepII positive bands 308 
on the injured side at day 2, day 6 and to a lesser extent at day 13 compared to the non-309 
injured contralateral nerve (Fig. 6d). The fact that the neuronal marker PGP9.5 band, 310 
dramatically decreased in intensity on the injured side several days after injury, probably 311 
reflects axon loss and atrophy, despite this STOML3 levels were increased. These results 312 
suggest that endogenous STOML3 is transported preferentially to the peripheral endings of 313 
sensory neurons41 to modulate mechanotransduction and that there is more STOML3 314 
transported to sensory endings after traumatic nerve injury. 315 
STOML3 and painful diabetic neuropathy   316 
Neuropathy is a prominent symptom of diabetes, and is often characterized by pain initiated 317 
by normally innocuous tactile stimulation in up to 20% of all patients42. We next asked 318 
whether OB-1 shows efficacy in a mouse model of painful diabetic neuropathy. We used the 319 
streptozotocin model (STZ) to induce mechanical hypersensitivity in mice with diabetes43. 320 
Between 6-7 weeks after STZ treatment, mice assigned to the drug and vehicle group began 321 
to display hypersensitivity to mechanical stimuli as reflected in increased frequency of paw 322 
withdrawal to von Frey filaments below 0.5 g (Fig. 7 a-d). Local treatment of the hindpaw 323 
glabrous skin with OB-1 (250 pmol per paw) substantially reversed the mechanical 324 
hypersensitivity 4 h after treatment whereas vehicle treatment was without effect (Fig 7a-d), 325 
PWT = 0.93 ± 0.13 g (OB-1 treated) vs 0.32 ± 0.06 (STZ), paired t-test, p = 0.0013 (Fig. 7b) 326 
or PWT = 0.63± 0.13 g (vehicle treated) vs 0.51± 0.01 (STZ), paired t-test, p = 0.31  (Fig. 327 
7d). The mechanical hypersensitivity returned to pre-drug treatment levels 24 h after a single 328 
treatment, as assessed by the mean 60% withdrawal threshold (Fig. 7a,b). 329 
 330 
 331 
Discussion   332 
Mammalian touch sensation is at last beginning to be unraveled at the molecular level44,45. 333 
Mechanosensitive ion channels, like Piezo1 and Piezo2, may prove difficult targets to exploit 334 
for pharmacological intervention46. For example, the early embryonic or post-natal lethality 335 
associated with Piezo1 or Piezo2 gene deletion47,48 and Piezo2’s role in proprioception12,13,49 336 
could prove problematic for the development of Piezo antagonists for therapeutic purposes. 337 
Here we describe an intersectional approach to modulate sensory mechanotransduction as our 338 
compounds should only be effective in cells in which both STOML3 and Piezo channels are 339 
present. This approach has the advantage that essential functions of Piezo proteins will not be 340 
directly affected by our small molecules yet we can gain selective and powerful inhibition of 341 
sensory mechanotransduction, especially under some pathophysiological conditions. We 342 
show that OB-1 has a powerful silencing effect on around 40% of mechanoreceptors and 343 
conclude that the transformation of the mechanical stimulus into receptor potential is severely 344 
impaired in these cells. Mechanosensitive currents were also inhibited by OB-1 in some 345 
nociceptors in our in vitro studies (Fig. 2f) and consistent with this mechanical thresholds 346 
were significantly elevated in many cutaneous C-fibers measured using the ex vivo skin-nerve 347 
preparation (Fig. 3). We propose that STOML3 inhibition silences mechanoreceptors 348 
primarily by reducing the displacement sensitivity of Piezo2 ion channels in 349 
mechanoreceptors. Mechanically gated currents in nociceptors may not be dependent on 350 
Piezo24, but deep sequencing studies have detected Piezo1 transcripts in many single mouse 351 
sensory neurons50 and Piezo1 channels are also strongly modulated by STOML32. Skin 352 
application of our STOML3 inhibitor OB-1 shows remarkable efficacy in reducing touch-353 
evoked pain behavior in two mouse models of neuropathic pain, but not in an SNI model. 354 
There is direct damage to the axons that innervate the sensitized skin in the CCI model that is 355 
associated with increased Stoml3 expression as well as increased STOML3 protein transport 356 
to the periphery (Fig. 6). Thus, we speculate that the remarkable efficacy of OB-1 in some 357 
pain models, including painful diabetic neuropathy is directly linked to changes in STOML3 358 
availability at sensory endings during disease progression. Stoml3 mRNA transcript 359 
expression has been detected in human tibial nerve and skin (http://gtexportal.org) and so it 360 
may be possible to detect changes in STOML3 in pathologies associated with neuropathic 361 
pain. In summary, we provide mechanistic validation of a novel pharmacological strategy to 362 
modulate sensory mechanotransduction to treat sensory disorders including pain.  363 
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 527 
  528 
Figure Legends 529 
Figure 1 Screening for small molecules that modulate STOML3 oligomerization. a, 530 
Schematic representation of BiFC analysis of protein-protein interactions used for small 531 
molecule screen. b, Signal development observed when STOML3-VC was used as prey and 532 
VN-tagged STOML3 variants that do not properly oligomerize were used as bait. c, The 533 
normalized slope of BiFC signal development was used as a measure of oligomerization.  ** 534 
p < 0.01 *** p < 0.001; unpaired t-test, two-tailed with p = 0.0046  (t=3.629 df=10)  535 
STOML3 vs. STOML3-V190P, p < 0.0001 (t=9.265 df=10) STOML3 vs. 536 
STOML3LR89,90VP,  p < 0.0001 (t=12.15 df=10) STOML3 vs. un-transfected cells; 537 
numbers indicate replicate TECAN experiments derived from 4-6 independent transfections; 538 
data are shown as individual slopes and mean ± s.e.m. d, Structures of hit compounds, the 539 
oligomerization blockers, OB-1 and OB-2. e,f,  Normalized slope of BiFC signal 540 
development in cells overexpressing Mus musculus or Homo sapiens STOML3 in the 541 
presence of OB-1 and OB-2 is shown. ** p < 0.01 *** p < 0.001; (i) unpaired t-test, two-542 
tailed with p=0.0002 (t=6.594 df=8) mmSTOML3 vs. mmSTOML3 + OB-1, p=0.0064 543 
(t=3.527 df=9) mmSTOML3 vs. mmSTOML3 + OB-2; numbers indicate replicate TECAN 544 
experiments derived from 4-6 independent transfections; data are displayed as individual 545 
slopes and mean ± s.e.m.; mean ± s.e.m. (e); (ii) Mann-Whitney U test, two tailed with p = 546 
0.0002 (Sum of  ranks 100 , 36  U 0) hsSTOML3 vs. hsSTOML3 + OB-1; numbers indicate 547 
replicate TECAN experiments derived from two independent transfections with 4 replicates 548 
each; data are shown as individual slopes and mean ± s.e.m. (f). g, Representative 549 
reconstructed dSTORM images of STOML3-FLAG overexpressed in N2a cells. h, 550 
Distribution of STOML3-FLAG domain size as detected by dSTORM imaging. ** p < 0.01 551 
*** p < 0.001; unpaired t-test, two-tailed, with p = 0.0023 (t=3.496 df=20) STOML3 vs. 552 
STOML3-V190P,  p < 0.0001 (t=6.533 df=26) STOML3 vs. STOML3 + OB-1,  p = 0.0006 553 
(t=3.994 df=23) STOML3 vs. STOML3 + OB-; numbers indicate N2a cells derived from at 554 
least 3 transfections. Each data point represents a single cell, for each cell the FHWM of 100 555 
randomly chosen domains was measured. 556 
 557 
Figure 2 Quantitative analysis of the effect of hit compounds on mechanotransduction. 558 
a, Schematic of pillar array analysis of mechanotransduction in N2a cells. b, Stimulus-559 
response curves for N2a treated with either OB-1 or OB-2; both compounds significantly 560 
inhibit mechanically-gated currents in N2a cells.  ** p < 0.01 *** p < 0.001; (i) Two-way 561 
ANOVA (stimulus response relationship) with p=0.0044 F (1, 131) = 8.390 Vehicle vs. OB-562 
1, p = 0.0388 F (1, 108) = 4.375 Vehicle vs. OB-2, numbers indicate stimulus response 563 
curves for N2a cells from  > 5 independent experiments, data are displayed as mean of 564 
individual bins ± s.e.m.;  (ii) Mann- Whitney U-test, two-tailed, Bin 250-500 with p=0.0146 565 
(U=27.00) Vehicle vs. OB1, p=0.0363 (U=23.50) Vehicle vs. OB2; numbers indicate cells 566 
stimulated in this range, data are displayed as mean current amplitude of individual bins ± 567 
s.e.m.. c, Hill plot of the concentration dependence of the OB-1 effect on the Piezo1 current 568 
in N2a cells.  ** p < 0.05; Mann-Whitney U test with p = 0.9266 Vehicle vs. 0.002µM OB-1, 569 
p = 0.1236 Vehicle vs. 0.02µM OB-1, p = 0.1112 Vehicle vs. 2µM OB-1, p = 0.0105 Vehicle 570 
vs. 20µM OB-1; numbers indicate N2a cells recorded in 2 (Vehicle), 4 (0.002µM), 3 571 
(0.2µM),  3 (2µM),  3 (20µM OB1)  independent experiments, data are displayed as mean 572 
current amplitude of individual bins ± s.e.m.. d, Schematic of pillar array analysis of 573 
mechanotransduction in acutely prepared DRG neurons. e, Stimulus-response curves for 574 
mechanoreceptors treated with either OB-1 or OB-2; both compounds significantly inhibit 575 
mechanically-gated currents activated by pillar deflections less than 50 nm, OB-1 576 
significantly inhibits currents gated by deflections up to 250 nm.  * p < 0.05 ** p < 0.01 *** 577 
p < 0.001; (i) Two-way ANOVA with p = 0.0007 (F (1, 80) = 12.56) Vehicle vs. OB-1, p = 578 
0.0017 (F (1, 78) = 10.59) Vehicle vs. OB-2; numbers indicate recorded stimulus-responses 579 
curves of DRG mechanoreceptors from at least 3 DRG preps; (ii) unpaired t-test, two-tailed,  580 
Bin 0-10 with p = 0.0462 (t=2.246 df=11) Vehicle vs. OB1, p = 0.0291 (t=2.477 df=12) 581 
Vehicle vs. OB2; (iii) Mann-Whitney U test, two tailed, Bin 10-50 with p = 0.0053 Vehicle 582 
vs. OB-1, p = 0.0068 Vehicle vs. OB-2, Bin 50-100 with p = 0.0224 Vehicle vs. OB-1, Bin 583 
100-500 with p = 0.0239 Vehicle vs. OB-1; numbers indicate currents measured from DRG 584 
mechanoreceptors, data from at least 3 DRG cultures derived from 5-7 weeks old mice; data 585 
are displayed as current amplitude, each bin displayed as mean of cell averages ± s.e.m..  f, 586 
Stimulus-response curves for nociceptors treated with either OB-1 significantly inhibit 587 
mechanically-gated currents in these cells.   * p < 0.05, (i) Two-way ANOVA with p = 588 
0.0263 (F (1, 80) = 12.56) (F (1, 78) = 10.59) Vehicle vs. OB-1, ns  (F (1, 78) = 10.59) 589 
Vehicle vs. OB-2, numbers indicate stimulus-response curves in DRG nociceptors derived 590 
from at least 3 DRG preparations derived from 5-7  weeks old mice ; data are displayed as 591 
current amplitude, each bin displayed as mean of cell averages ± s.e.m; (ii) Mann-Whitney U 592 
test with p =0.0388 (U=10.00, Bin 100-250) Vehicle vs. OB-1, p = 0.0087 (U=2.000, Bin 593 
250-500) Vehicle vs. OB-2; numbers indicate currents measured in DRG nociceptors, at least 594 
3 DRG preparations derived from 5-7  weeks old mice; data are displayed as current 595 
amplitude, each bin displayed as mean of cell averages ± s.e.m.. g-i, In the presence of OB-1 596 
there was no detectable difference in action potentials generated by current injection in either 597 
(h) mechanoreceptors or (i) nociceptors, statistical tests applied: (i) Mann-Whitney U test 598 
(Mechanoreceptors) with p = 0.215 (U=19); (ii) Student’s t-test  (Nociceptors), two-tailed 599 
with p = 0.4743 (F=2.682, DFn=11, Dfd=12); numbers indicate cultivated neurons recorded 600 
from 3 mice in 3 independent experiments; data are displayed as current amplitudes and mean 601 
of individual bins ± s.e.m.. 602 
 603 
Figure 3 Mechanoreceptors can be silenced with local OB-1 treatment.  604 
a, Inset: Electrical search protocol schema. A micro electrode (~1MΩ) was used to deliver 605 
electrical stimuli at two distant points of the saphenous nerve trunk in order to trace 606 
electrically identified units to their receptive fields. Proportions of mechanoINsensitive fibers 607 
are shown. Three hours after local OB-1 treatment (250 -500 pmol OB-1 per paw) an increase 608 
in mechanically INsensitive Aβ-fibers was observed; note that mechanosensitivity had 609 
recovered 24h post-injection.  ** p < 0.01 *** p < 0.001; Fisher's exact test with p < 0.0001 610 
Aβ-fibers Vehicle vs. OB-1(male & female mice), p < 0.0001 (Aβ-fibers Vehicle vs. OB-1 611 
(male), p = 0.0033 Aβ-fibers Vehicle vs. OB-1(female), p = 1.0 ( Aβ-fibers OB-1(male)  vs.  612 
OB-1 (female), p = 0.0028 Aβ-fibers OB-1 vs.  OB-1 wash-out, p = 0.2465 Aδ-fibers Vehicle 613 
vs. OB-1, p = 1.0 C-fibers Vehicle vs. OB-1; numbers indicate single sensory fiber recordings 614 
derived from 10-20 independent experiments using adult mice (Fig 3a-e together), data are 615 
displayed as percentage of individual fibers. b, Stimulus response function of C-MH fibers is 616 
shown using a series of ascending displacements (32 – 1024 µm). C-MH fibers were 617 
significantly less responsive in OB-1 treated mice compared to vehicle treated controls.  * p < 618 
0.05; Two-way ANOVA with p = 0.0412 (F=4.208, DFn=1, Dfd=257) Vehicle vs. OB-1; 619 
numbers indicate fibers recorded in 10-20 independent experiments; data are displayed as 620 
mean number of action potentials ± s.e.m.. c, Mean force thresholds for C-MH fiber 621 
discharge are displayed showing a significant elevation of mechanical thresholds. * p < 0.05; 622 
Mann-Whitney U test with p=0.0233 (U = 89); numbers indicate single sensory fiber 623 
recordings derived from 10-20 independent experiments using adult mice (Fig 3a-e together); 624 
data are displayed as individual thresholds and mean threshold ± s.e.m.. d, For C-M fibers 625 
there was no significant difference between vehicle and OB-1 treated stimulus response 626 
functions. Statistical test applied: Two-way ANOVA with p = 0.3563 (F=0,8579,DFn=1, 627 
Dfd=115); numbers indicate single sensory fiber recordings derived from 10-20 independent 628 
experiments using adult mice (Fig 3a-e together); data are displayed as mean number of 629 
action potentials ± s.e.m.. e, Mean  force thresholds for C-M fiber were also not different 630 
between vehicle and OB-1 treatments. Statistical test applied: unpaired t-test, two tailed with 631 
p = 0.7860 t=0,2756 df=18;numbers indicate single sensory fiber recordings derived from 10-632 
20 independent experiments using adult mice (Fig 3a-e together); data are displayed as 633 
individual thresholds and mean threshold ± s.e.m.).  634 
 635 
Figure 4 OB-1 reduces the touch perception in mice 636 
A tactile perception task for head-restrained mice. a, Mice were trained to report a single 637 
tactile pulse stimulus (inset shows stimulus voltage command pulse for all 8 amplitudes). 638 
Trial structure: mice were trained to (1) hold the rest sensor and wait for a stimulus; (2) on 639 
detection of the stimulus reach and press the target sensor within 500 ms from stimulus onset; 640 
(3) obtain water reward by licking providing it was a successful trial. b, Psychometric curves 641 
to different amplitude tactile stimuli are affected by injection of OB-1 into forepaw. Curves 642 
were constructed with a sigmoid fitting of the mean hit rates to 7 different amplitudes of 643 
tactile stimuli and a no stimulus trial (false alarm). Three conditions are displayed, injection 644 
of the vehicle (black), injection of OB-1 (magenta) and a recovery session with no prior 645 
injection (grey). c, OB-1 application to forepaw attenuates perception of near threshold tactile 646 
stimuli. Grouped hit rates to 3 threshold amplitude values (125, 175 and 275 µm) from 5 647 
mice were significantly reduced after OB-1 injection as compared to hit rates after vehicle 648 
injection or on recovery session without prior injection. Statistical tests were made on hit 649 
rates after subtraction of the corresponding false alarm rates. * p < 0.05; Wilcoxon Signed 650 
Rank Test with p = 0.026 Vehicle vs.. OB-1,  p = 0.0043 OB-1 vs.. OB-1 Wash-out, p = 0.12 651 
Vehicle vs.. OB-1 Wash-out; numbers indicate mice treated, data are displayed as average of 652 
individual hit rates of each mouse, grouped for 3 amplitudes ± s.e.m.. 653 
 654 
Figure 5 Tactile-evoked pain can be treated with OB-1. 655 
a, Development of tactile-evoked pain after traumatic nerve injury is shown. Paw withdrawal 656 
thresholds (PWT) to varying forces of von Frey filaments before and after unilateral CCI 657 
were measured. Note that after nerve injury Stoml3-/- mice develop significantly less tactile-658 
evoked pain compared to wild type animals. *** p < 0.001 ** p < 0.01; Two-way ANOVA 659 
with p < 0.0001 (F=107,65, DFn=1, Dfd=159) WT vs. Stoml3-/- and  Bonferroni’s multiple 660 
comparison with p >  0,9999, t = 1,488  df=159  (d0),  p = 0,3728, t = 2,056 df = 159  (d2),  p 661 
= 0.0027, t = 3,701 df = 159  (d4),  p = 0.0006,  t = 4,104 df = 159   (d6), p = 0.006, t = 4,096 662 
df = 159   (d8), p = 0.003,  t = 4,273 df = 159   (d10), p < 0.0001,  t =5,255df = 159   (d12), p 663 
= 0.0303,  t = 2,977 df = 159   (d14), p = 0.0048,  t = 3,535 df = 159   (d21); numbers indicate 664 
numbers of adult mice examined from two cohorts tested independently; data are displayed as 665 
mean of individual median PWTs ± s.e.m.. b, Paw withdrawal latencies (PWLs) to a standard 666 
radiant heat source applied to the ipsilateral hind paw of wild type and Stoml3-/- mice before 667 
and after CCI were not different between the genotypes. ** p < 0.01 * p < 0.05; Mann-668 
Whitney U test with p = 0.0065 WT (U = 1.500) naive  vs. WT CCI, p = 0.0325 (U = 4.500 ) 669 
Stoml3-/- naive  vs. Stoml3-/- CCI, p = 0.2532 (U= 10.50) WT CCI vs. Stoml3-/- CCI ; numbers 670 
indicate mice treated (one cohort); data are displayed as mean PWL ± s.e.m.). c, Treatment of 671 
naïve mice with OB-1 does not alter PWTs, paws of mice treated, (12= ipsi and contra; 672 
6=ipsi, 6=contra) one cohort, ns Mann-Whitney U test with p = 0.2042 (U = 22) Naïve vs 673 
OB-1 treated, p = 0.4545 (U = 14) OB-1 treated vs. Vehicle treated; numbers indicate adult 674 
mice treated; data are displayed as mean of individual median PWTs. d-e, PWT measured 675 
before and after nerve injury shows clear hypersensitivity that is not reversed by injection of 676 
vehicle, note that local ipsilateral treatment of the neuropathic paw with OB-1 effectively 677 
normalizes PWT, but treatment of the contralateral paw does not (e). ** p < 0.01 * p < 0.05; 678 
(i) paired t-test, two tailed with p = 0.0028 (t=3,570 df=15) CCI male & female vs. CCI + 679 
OB-1 male & female), p = 0.0066 (t=3,811 df=7) CCI male vs. CCI + OB-1 male, p = 0.0193 680 
(t=3,022 df=7) CCI female vs. CCI + OB-1 female),   (ii) Mann-Whitney U test  with p= 0.25 681 
(U = 7) CCI ipsi vs. OB-1contralateral injected ipsilateral measured; numbers indicate adult 682 
mice examined from three cohorts tested independently; data are displayed as mean of 683 
individual median PWTs; ± s.e.m.. f, Note that alleviation of hypersensitivity with OB-1 684 
treatment is indistinguishable from gabapentin treatment. ** p < 0.01; Wilcoxon matched-685 
pairs signed rank test with p = 0.0013 (t=6,518 df=5 ) CCI vs. CCI + Gabapentin; numbers 686 
indicate adult mice treated (one cohort tested), data are displayed as mean of individual 687 
median PWTs; error bars indicate s.e.m.. g, Dose-response relationship of OB-1 is shown, 688 
ED50 = 4.42 µM or approximately 20 pmol. *** p < 0.001 ** p < 0.01; Mann-Whitney U test 689 
with p = 0.7265 Vehicle vs. 0.5µM OB-1, p = 0.0749 Vehicle vs. 5µM OB-1, p = 0.0002 690 
Vehicle vs. 50µM OB-1, p = 0.0044  Vehicle vs. 100µM OB-1; numbers indicate drug 691 
treatments, adult mice came from 9 cohorts; data are displayed as mean of individual median 692 
PWTs; error bars indicate s.e.m.. h, Measurement of PWTs over time; the maximal analgesic 693 
efficacy developed between 3h and 9h after local OB-1 injection; numbers indicate mice 694 
treated (one cohort tested); data are displayed as mean of individual median PWTs. i, No 695 
significant change in PWT was measured in Stoml3-/- mice with CCI  after local 696 
administration of OB-1, paired t-test with  p =0.125 ( Sum of signed ranks = 13.00  Number 697 
of pairs = 6) CCI, Stoml3-/-  vs. CCI, Stoml3-/- + OB-1; numbers indicate drug treatments (one 698 
cohort tested); data are displayed as mean of individual median PWTs; error bars indicate 699 
s.e.m.. j, Stoml3 copy number derived from lumbar DRG L4-6  determined using real-time 700 
PCR showing an ipsilateral up-regulation of Stoml3 mRNA. Note that the last two bars 701 
represent data from Stoml3-/- mice. ** p < 0.01, * p < 0.05; Mann-Whitney U test with 702 
p=0.0079 (U = 0) CCI ipsi vs. contra, p=0.0357 (U = 0) naive ipsi vs. CCI ipsi, p=0.7000 (U 703 
= 4)  naive ipsi vs. contra numbers indicate RNA preparations with L4-6 of two adult mice 704 
pooled for one RNA preparation; data represent the mean copy number ± s.e.m.). 705 
 706 
Figure 6 Regulation of STOML3 in painful neuropathy   707 
a, Cytochemistry of lumbar DRGs from Stoml3+/lacZ mice that had received a nerve injury 708 
(CCI). b, Note that the number of lacZ-positive neurons increased after a unilateral CCI 709 
predominantly in large cells.***p < 0.001; Fisher's exact test with p < 0.0001; numbers 710 
indicate cells counted analyzing 23 images obtained from 10 adult Stoml3lacZ/lacZ mice or 17 711 
images obtained from adult Stoml3+/lacZ mice. c, schematic of the modified locus of StrepII 712 
knockin mice. d, Western blots of protein extracts taken from the sciatic nerve of 2 adult 713 
Stoml3StrepII/StrepII knockin mice per protein preparation subjected to unilateral CCI. Extracts 714 
were made from two mice per time point note that a specific StrepII-STOML3 band was 715 
detected ipsiliateral and contralateral to the injury at all time points (bands are not detected in 716 
protein extracts from sciatic nerves of  2 adult Stoml3-/- mice per protein preparation). At day 717 
2 (d2), day 6 (d6) and to a lesser extent day 13 (d13) post-injury there was clearly much more 718 
protein found on the injured side compared to the uninjured sciatic nerve. The same protein 719 
extracts were probed with antibodies against PGP9.5 a neuronal marker which decreased 720 
dramatically on the injured side consistent with the known loss and atrophy of axons in the 721 
CCI model.  722 
 723 
Figure 7 Inhibition of STOML3 alleviates painful diabetic neuropathy 724 
a, Diabetic peripheral neuropathy was induced using streptozotocin (STZ). After 725 
development of peripheral neuropathy, diabetic mice received a single injection of OB-1 or 726 
vehicle respectively into the plantar surface of the hind paw. a, Three hours after injection, 727 
OB-1 treated mice showed attenuated mechanical sensitivity displayed as percentage of 728 
withdrawal to increasing von Frey filaments. *** p < 0.001; Two-way ANOVA with p > 729 
0.0001 (F (1, 132) = 28,07)  OB-1 vs. STZ and Bonferroni's multiple comparison with p > 730 
0.9999 (t = 0,7867 df = 132) (0.07g), p > 0.9999 (t = 1.377 df= 132)  (0.16g), p = 0.0033 (t = 731 
3.539 df= 132)  (0.4g), p = 0.0123 (t = 3.146 df= 132)  (0.6g), p = 0.0404 (t = 2.753 df= 132)  732 
(1g), p > 0,9999, t = 1.377 df= 132  (1.4g) ; numbers indicate adult mice treated; data are 733 
displayed as mean of individual PWTs; error bars indicate s.e.m.)  b, mechanical thresholds 734 
required to elicit 60% withdrawal frequency.** p < 0.01, *** p<0.001;  (i) Wilcoxon Signed 735 
Rank Test with p = 0.0005 (Sum of signed ranks  -78,00 Number of pairs 12, Naive vs. 736 
STZ, (ii) paired t-test, two-tailed with  p = 0.0013 (t=4,287 df=11) STZ vs. STZ + OB1, p = 737 
0.0004 (t=4,939 df=11) STZ + OB1 vs. OB-1 Wash-out; numbers indicate mice treated, two 738 
cohorts were  tested independently; data are displayed as mean of individual PWTs; error 739 
bars indicate s.e.m.. c,d, Diabetic mice in the vehicle treated group showed no reversal of 740 
mechanical hypersensitivity. ** p < 0.01 (i) ordinary Two-way ANOVA with p = 0.0765  (F 741 
(1, 144) = 3,184) STZ vs. STZ+ Vehicle; (ii) Wilcoxon Signed Rank Test with p= 0.0765,  742 
Naive vs. STZ; (ii) paired t-test, two-tailed with p= 0.3125 (t=1,054 df=1) STZ vs. STZ + 743 
Vehicle, p=0.0859  (t=1,871 df=12) STZ + Vehicle vs. Vehicle Wash-out; numbers indicate 744 
mice treated from two cohorts tested independently; data are displayed as mean of individual 745 
PWTs; error bars indicate s.e.m. 746 
  747 
Online Methods 748 
 749 
The experiments in this study were carried out on adult inbred male or female mice (adult 750 
C57Bl/6n obtained from Charles River, Sulzfeld, Germany) or adult mice generated and 751 
breed in the laboratory (Stoml3-/-, Stoml3StrepII or Stoml3lacZ). All experiments were performed 752 
in compliance with German and European laws for the use of animals in research and with 753 
appropriate permits from the Berlin authorities. Animals were kept under controlled 754 
temperature and a 12–h light, 12–h dark cycle with lights on at 06:00 A.M. Behavioral tests 755 
were conducted during the light phase. and the experimenter was blinded to treatment and 756 
genotype unless otherwise stated. 757 
 758 
Statistics 759 
All data were tested for normal distribution. Appropriate statistical tests applied for data 760 
analysis are referred to in the figure legend. Multiple comparisons were performed by 761 
repeated measures two-way ANOVA followed by Bonferroni post hoc test. Significance 762 
levels of p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) were used. Statistical analyses and 763 
exponential fits were made using the GraphPad Prism or Igor Pro 6.11. software. No 764 
statistical methods were used to pre-determine sample sizes but our sample sizes are similar 765 
to those reported in previous publications1–11. Experimenters were always blinded to 766 
treatment, or genotype unless otherwise stated. No special randomization procedures were 767 
used for assigning groups. 768 
 769 
Molecular biology 770 
Expression Constructs 771 
Constructs for BiFC analysis were created by inserting the gene of interest, in frame, into the 772 
multiple cloning site of pBiFC-VC155 or pBiFC-VN173. Point mutations were introduced 773 
using PCR-based site-directed mutagenesis.  774 
RT-PCR analysis  775 
Lumbar L3-L6 dorsal root ganglia (DRG) were dissected from CCI and control mice, pooled 776 
and total RNA extracted with the TRIzol method (Invitrogen) as per manufacturer 777 
recommendations and treated with the TURBO DNA-free™ Kit to avoid DNA 778 
contamination. RNA was quantified using NanoDrop 2000 UV-Vis spectrophotometer 779 
(Thermo Scientific) and reverse-transcribed using SuperScript® III Reverse Transcriptase 780 
(Invitrogen). TaqMan Quantitative RT-PCR was used to detect the expression of STOML3 781 
mRNA with 5´-GGAAGCCAGAGCCAAGGT-3´ and 5´-TGCAGGTACCGAAGTTGGA-782 
3´primers in combination with the TaqMan probe #53 from Roche Universal Probe Library. 783 
Each sample was performed in triplicate in an ABI Prism 7700 Sequence Detection System 784 
(Thermo Scientific).  785 
 786 
Cell culture 787 
HEK-293 cells (passage numbers 4-20) were cultured in DMEM plus 10% fetal calf serum 788 
(FCS). Neuro2A (N2a) cells were cultured in DMEM/Opti-MEM media plus 10% FCS. Cell 789 
lines were originally sourced from the ATCC and regularly checked for mycoplasma 790 
contamination. Sensory DRG neurons were isolated from 4 week old Mus musculus 791 
(C57Bl/6). Approximately 40 ganglia were collected from each mouse and individual cells 792 
were isolated by treating ganglia with 1 µg/ml collagenase IV for 30 min, followed by 1 ml 793 
of 0.05% trypsin, in PBS, for 5-20 min at 37°C. Enzyme-treated ganglia, in DMEM/F-12 794 
media containing 10% Horse Serum (HS), were disrupted by gently passaging through a 20G 795 
needle; cells were then collected by centrifugation (1000 rpm, 3 min), washed and finally re-796 
suspended in DMEM/F-12, 10% HS media (at no point were neurotrophins added to the 797 
culture). Experiments with isolated sensory neurons were conducted within 24-36 hours of 798 
isolation. 799 
 800 
High through-put screen 801 
HEK-293 cells were cultured to approximately 70% confluence; cells were co-transfected 802 
with plasmids encoding STOML3-VC and STOML3-VN using Fugene-HD, as per 803 
manufacturer’s instructions. The transfection reaction proceeded for 8 h before cells were 804 
recovered and re-suspended in DMEM media containing 25 mM HEPES and lacking phenol 805 
red. Cells were plated on PLL-coated 384 well plates using an automated dispenser (EL406 806 
Microplate Washer Dispenser). Plates already contained compounds from the ChemBioNet 807 
library (www.chembionet.info) a library containing small molecules with drug like 808 
properties12. Development of the YFP fluorescence signal was monitored overnight (15 h), 809 
with readings taken every 3 h (ex: 515 ± 8 nm, em: 535 ± 8 nm). Overnight monitoring of 810 
signal development was performed with a Freedom Evo workstation and a SafireII plate 811 
reader for fluorescence measurement (Tecan Group Ltd, Männedorf, Switzerland), and an 812 
integrated STX44-ICSA automated plate incubator (Liconic AG, Mauren, Liechtenstein). 813 
Experiments were repeated with 20 plates each day until the entire compound library had 814 
been screened and data was normalized to in-plate controls. 815 
Compounds of interest were selected from the slope of YFP-signal vs time. Each well was 816 
compared to the average slope of in-plate positive controls (normalized percent activity), and 817 
compared to the mean and standard deviation of all samples on a plate (without the controls), 818 
giving a Z score as a measure of statistical significance9. One hundred and fifteen (115) 819 
inhibitors that significantly decreased the slope with a Z score < -3 were selected for further 820 
analysis. After re-screening in triplicate just 21 of the initially identified hit molecules were 821 
confirmed. Compounds that were themselves fluorescent or those that had significant effects 822 
on cell viability were discarded.  823 
 824 
dSTORM imaging 825 
N2a cells were cultured on EHS-Laminin coated precision coverglass, thickness 0.17mm, and 826 
transfected with a STOML3-FLAG plasmid. After overnight incubation, cells were treated 827 
for 3 hours with 20 µM compound, or DMSO as a control. Cells were fixed  (15 min, 4% 828 
PFA), permeabilized  (0.05% TritonX 100, 5 min) and blocked (phosphate buffered saline 829 
(PBS) containing 10% fetal goat serum (FGS), 37°C, 1 hr). Cells were labeled with mouse 830 
anti-FLAG antibody (M2 clone Sigma #F1084, 1:100 in PBS containing 10% FGS). The 831 
secondary antibody was an Alexa647-conjugated, goat anti-mouse antibody (1:100 in PBS 832 
plus 10% FGS, 1 h, 37°C). After staining, the samples were fixed again. Prior to dSTORM 833 
imaging, coverslips were mounted in dSTORM buffer PBS, pH 7.4, containing an oxygen 834 
scavenger (0.5 mg/ml glucose oxidase), 40 mg/ml catalase, 10% (w/v) glucose and 100 mM 835 
MEA 13.  836 
The custom-built dSTORM system, based on a Nikon Ti microscope, was described in detail 837 
previously 14. Before acquisition, we illuminated the Alexa647-labeled sample with 643 nm 838 
to switch fluorophores into the OFF state. After molecules started blinking, we acquired a 839 
sequence of frames (typically 10,000–20,000) using a 100x 1.49 NA objective, a 1.5 840 
magnification lens and non-binned EMCCD array. An exposure time of 30 ms was used to 841 
ensure good signal-to-noise and a high number of blinking single molecules/frame.  842 
In order to aid drift correction PLL-coated Tetra-speck fluorescent beads were allowed to 843 
adhere to the sample overnight. Localization: Single molecules were localized using open 844 
source software rapidSTORM 3.2 15. The source images are first smoothed via median 845 
operator followed by a fill-hole operation to reduce noise. In these ‘de-noised’ images, 846 
rapidSTORM performs a Gaussian fit (Levenberg–Marquardt parameter estimation) to each 847 
intensity spot, and fit quality and peak maxima were used as quality measures for 848 
localization. This fit yields the precise position of the single molecule with sub-pixel 849 
accuracy, the total intensity of the single molecule event and the frame number of the event. 850 
Sample drift was corrected using fiduciary beads in the sample as reference points (custom 851 
written algorithm, GREGOR). 852 
For analysis of STOML3 domain size, all reconstructed images were blinded and then from 853 
each imaged cell 100 individual dots were cropped (size: 20 x 20 pixels). A 2D-Gaussian fit 854 
was calculated using the Igor software (WaveMetrics, USA). The x-width and y-width for 855 
each dot were included in the data set as domains were not necessarily circular.  856 
 857 
Chemical Synthesis 858 
 859 
The molecules OB-1 and OB-2 were structurally compared using a Tanimoto coefficient. The 860 
structures were translated with a FCFP-4 protocol and the resulting fingerprints did not show 861 
any significant similarity. Detailed chemical information for OB-1 and OB-2 can be found 862 
with the following links: 863 
OB-1 http://www.chemspider.com/Chemical-Structure.948385.html 864 
OB-2 http://www.chemspider.com/Chemical-Structure.9820833.html  865 
For de novo synthesis 5.6 g of ethyl-3-oxo-3-phenylpropanoate (29.06 mmol) was solubilized 866 
in 50 ml toluene and 525 mg (1.45 mmol) of Cu(OTf)2 was added. Next, 1.57 g (14.5 mmol) 867 
of benzoquinone was solubilized in 20 ml of toluene and added dropwise to the reaction 868 
mixture followed by reflux for 3 h. The mixture was quenched with NH4Cl and extracted 869 
three times with ethyl acetate. The combined organic layers were washed with brine and 870 
dried with Na2SO4. The crude product was purified by chromatography on silica gel eluting 871 
with a gradient of Hex/EE (10:1) to give 2.24 g of ethyl-5-hydroxy-2-phenylbenzofuran-3-872 
carboxylate (Yield: 27 %) This product was an intermediate before final synthesis of OB-1. 873 
Next 0.5 g (1.77 mmol) of ethyl-5-hydroxy-2-phenylbenzofuran-3-carboxylate was 874 
solubilized in 20 ml DMF and 1.2 eq Cs2CO3 (0.7 g, 2.1 mmol), 0.1 eq CuI (33 mg, 0.17 875 
mmol) and 285 mg (1.77 mol) 5-chloro-1-mehtyl-4-nitro-1H-imidazole were added. The 876 
mixture was stirred for 3 h at room temperature. The organic solvent was removed under 877 
reduced pressure.  The crude product was purified by chromatography on silica gel eluting 878 
with a gradient of Hex/EE (3:2) to give 644 mg of ethyl-5-(1-methyl-4-nitro-1H-imidazol-5-879 
yloxy)-2-phenylbenzofuran-3-carboxylate (Yield: 89 %). 880 
 881 
Electrophysiology 882 
Whole-cell, patch-clamp recordings were conducted as previously described2,10, using patch 883 
pipettes with a tip resistance of 3-6 MΩ, filled with a solution of: 110 mM KCl, 10 mM 884 
NaCl, 1mM MgCl2, 1 mM EGTA and 10 mM HEPES, adjusted to pH 7.3 with KOH. For 885 
experiments on DRG neurons 10 mM QX-314 was added to the pipette to block voltage-886 
gated sodium channels10. Extracellular solutions contained 140 mM NaCl, 4 mM KCl, 2 mM 887 
CaCl2, 1 mM MgCl2, 4 mM glucose, 10 mM HEPES, adjusted to pH 7.4 with NaOH. A Zeiss 888 
200 inverted microscope and an EPC-10 amplifier in combination with Patchmaster software 889 
was used, data was analyzed using Fitmaster software (HEKA Electronik GmbH, Germany). 890 
Mechanical stimuli were applied using a polished glass probe driven by the MM3A 891 
micromanipulator (Kleindiek Nanotechnik, Germany). Mechanical stimuli were applied by 892 
either; indenting the cell soma or by culturing cells on elastomeric pillar arrays and applying 893 
the stimulus to the cell-substrate interface by deflecting an individual pilus. For a detailed 894 
description of experiments using pillar arrays10. Images were obtained of the pilus before and 895 
after deflection and images were analyzed off-line to determine the exact deflection for each 896 
data point. Images were obtained using a 40x LD objective and a CoolSNAP EZ CCD 897 
camera. The collection of stimulus-response data using pillar arrays generates data sets with 898 
variation in both x and y. In order to effectively compare groups for each cell studied we 899 
binned response data by stimulus size in the following bins: 0-10, 10-50, 50-100, 100-250, 900 
250-500, 500-1000 nm. For each cell, current amplitudes within each bin were averaged and 901 
then bins averaged between cells- we then tested for significance by testing whether the 902 
current amplitude for a given stimulation range (i.e. bin) differed between samples. To 903 
distinguish mechanoreceptors from nociceptors in the mixed population of acutely prepared 904 
DRG neurons, the shape of the generated action potential (AP) was used. For quantitative 905 
analysis of mechanosensitivity we measured responses in the most sensitive sub-population 906 
of mechanoreceptors with APs lacking a hump in the falling phase and a full width at half 907 
maximum (FWHM) of at least 0.7 ms, (average, ± s.e.m.: 0.9 ± 0.04 ms) 10. 908 
To test the effect of compounds on stomatin modulation of ASIC currents CHO cells were 909 
transfected with vectors encoding Stomatin and ASIC3, in a ratio of 4:1 using lipofectamine, 910 
as per manufacturer’s instructions. Cells were incubated with 20 µM OB-1 for 3 hours in 911 
extracellular buffer (see above), and OB-1 was maintained in the media during 912 
electrophysiological experiments. ASIC3 channels were gated by applying solutions of pH6 913 
and pH4, and both the transient and sustained peak current density was measured. 914 
 915 
Ex vivo skin nerve preparation 916 
The skin-nerve preparation was used essentially as previously described to record from single 917 
primary afferents7. For the electrical search protocol a microelectrode (1MΩ) was 918 
maneuvered to contact the epineurium of the nerve trunk and an electrical stimulation was 919 
delivered at 1 s intervals with square wave pulses of 50 – 500 ms duration. In most filaments 920 
3-5 single units were counted. The electrical nerve stimulation was done at 2 distant sites of 921 
the saphenous nerve to trace electrically identified units to their receptive fields. Mechanical 922 
sensitivity of single units was tested by mechanical stimulation with a glass rod. A computer-923 
controlled nanomotor (Kleindiek, Reutlingen, Germany) was used to apply controlled 924 
displacement stimuli of known amplitude and velocity. The probe was a stainless steel metal 925 
rod and the diameter of the flat circular contact area was 0.8 mm containing a force 926 
transducer (Kleindiek, Reutlingen, Germany). The signal driving the movement of the linear 927 
motor and raw electrophysiological data were collected with a Powerlab 4.0 system 928 
(ADInstruments) and spikes were discriminated off-line with the spike histogram extension 929 
of the software.   930 
 931 
Tactile perception task 932 
 933 
Male C57Bl6/J mice were anaesthetized and a lightweight metal headholder was implanted to 934 
the skull using glue (Loctite 401, Henkel) and dental cement (Paladur®, Heraeus). Mice were 935 
habituated to the head-restraint and the behavioral setup over 1-2 days. Mouse licking and 936 
forepaw behavior was monitored with three custom-made capacitance sensors: a licking 937 
sensor, a rest sensor and a target sensor that provided an online monitor of paw or tongue 938 
contact. The rest sensor was a ball (diameter: 6 mm) mounted on a glass rod of 30 mm length, 939 
glued to a piezoelectric bender (PICMA® Multilayer Piezo Bender Actuator, Physik 940 
Instrumente). The piezo generated a 30 ms cosine tactile pulse via a piezo amplifier system 941 
(Sigmann Elektronik). The stimulus amplitude was calibrated with a high-speed (300 Hz) 942 
camera (Dalsa Genie HM640). The target sensor (diameter: 6 mm) had a start position of 10 943 
mm horizontally in front of the rest sensor and was attached to a Fisso 3D articulated arm on 944 
a linear translation stage (ST9-100-2 eco-P, ITK Dr. Kassen GmbH, Germany). Mice were 945 
water restricted and given approximately 4 x 0.6 µl water rewards on condition of touching 946 
the target sensor within a defined latency from stimulus onset and licking the water dispenser. 947 
The target sensor moved to the start position at the start of a new trial and away from the 948 
mouse at the end of the trial. Inter-trial interval was randomized between 7 and 13 s. White 949 
noise was played throughout the trial. The response window (rewarded stimulus-to-touch 950 
latency) was reduced during behavioral training to 500 ms during the testing session. Mice 951 
were trained with high amplitude stimuli (620 µm) and then tested in the same session with 952 
seven different stimulus amplitudes (in µm: 45, 80, 125, 170, 275, 385, 620) and a no-953 
stimulus trial to calculate the false alarm rate. Stimuli were presented in a randomized order. 954 
The setup was controlled with custom written software in LabView 10.0 (National 955 
Instruments 2010). Drug injections of OB-1 or DMSO alone were dissolved in Ringer’s 956 
solution (in mM: 135 NaCl, 5 KCl, 5 HEPES, 1.8 CaCl2, 1 MgCl2) to make the OB-1 and 957 
vehicle solution. Approximately 5 µl was injected into the digits with a glass micropipette 958 
and 10 µl into the palm with a Hamilton syringe. During the injection procedure, the mouse 959 
was anaesthetized with isoflurane (1.5 to 2.0 % in O2). The experimenter was not blinded to 960 
treatment. 961 
To construct the psychometric curves we first averaged the rates of pressing the target sensor 962 
within 500 ms from stimulus onset across 5 mice. Next we fitted the data with a sigmoid 963 
function in Igor Pro 6.11 (WaveMetrics): 964 
 ݂(ݔ) = ܾܽݏ݁ +	 ௠௔௫ଵାୣ୶୮	(ೣೊఱబషೣೞ೗೚೛೐ )
  965 
Mouse Pain Models and Behavioral Experiments 966 
Chronic Constriction Injury 967 
In deeply anaesthetized mice using isoflurane delivered in 100% O2 (Univentor 410 968 
Anaesthesia unit; Univentor, Malta), four loose silk (5/0; Catgut GmbH Markneukirchen) 969 
ligatures were placed around the sciatic nerve at the level of the right mid-thigh as described 970 
previously5. 971 
 972 
Spared Nerve Injury 973 
In deeply anesthetized mice (see above) a skin and muscle incision was made at the thigh to 974 
reveal the sciatic trifurcation. Distal to the sciatic’s trifurcation, nerve pieces (2-4 mm) of the 975 
sural as well as the common peroneal nerves were removed leaving the tibial nerve intact. In 976 
sham controls the surgery was performed without transecting the nerves. Wounds were 977 
closed with wound clips before anesthesia was terminated. 978 
 979 
NGF-induced Hyperalgesia 980 
 981 
A single dose of NGF (1 μg/g body weight) was injected intraperitoneal (i.p.) into adult mice 982 
and behavioral testing was performed 6h, 24h, 48h, and 72 hours post injection. 983 
Diabetic Neuropathy Model 984 
Eight week old C57Bl/6 mice were used for diabetes experiments. Diabetes was induced 985 
using previously reported protocols 11,16. Briefly, 6 consecutive intraperitoneal injections of 986 
streptozotocin (STZ, Sigma-Aldrich, # S0130) were given with 24h intervals at 60 mg/Kg 987 
body weight in citrate buffer (0.05 M, pH 4.5) to induce diabetes. Blood glucose was 988 
maintained between 400 and 500 mg/dL throughout the experimental period.  Mechanical 989 
sensitivity was measured and only those mice showing increased sensitivity to von Frey 990 
filaments as compared to basal sensitivity were selected for OB-1 testing. Vehicle or OB-1 991 
(approximately 20 µl solution, 250 pmol per paw) was injected subcutaneously into 992 
intraplantar surface of diabetic mice under mild isoflurane anesthesia and mechanical 993 
sensitivity was measured from both injected (ipsilateral) and non-injected (contralateral) 994 
paws at 4 and 24h post-injection. 995 
 996 
Assessing pain behavior. 997 
Mice were allowed to habituate to the testing apparatus (acrylic chambers 10 × 10 cm in size, 998 
suspended above a wired mesh grid) one hour prior to behavioral testing. Calibrated von-Frey 999 
hair monofilaments (Aesthesio® set of 20 monofilaments, Ugo Basil) were applied to the 1000 
plantar surface of the hind paw in order to deliver target forces from 0.008 grams to 4 grams 1001 
increasing in an approximately logarithmic scale. A single von Frey stimulus lasted for two 1002 
seconds unless the mouse withdrew its paw. The up-and-down method described by Chaplan 1003 
8 was adapted as follows: Testing began with a 0.4 g filament applied three times  A positive 1004 
response was noted if paw withdrawal was seen to all three stimuli, so that the next smallest 1005 
filament was tested next. A negative response was noted when  paw withdrawal was not seen 1006 
to at least one stimulus which was followed by testing with the next largest filament. Paw 1007 
withdrawal thresholds were calculated as the median of 23 to 30 determined turning points. 1008 
 1009 
A focused, radiant heat light source (IITC Life Science Inc.) was used to measure paw 1010 
withdrawal thresholds to heat as previously described. The light beam created a focused spot  1011 
of 4x6 mm on the hind paw. The time to paw withdrawal in response to a constantly 1012 
increasing heat stimulus (maximal active intensity = 25% of the light source) with a cutoff of 1013 
20 seconds was determined. Heat stimuli were repeated 6 times for each paw with a stimulus 1014 
interval of 1 minute.  1015 
 1016 
Generation of Stoml3LacZ and Stoml3StrepII mice 1017 
The C57BL/6J mouse BAC clones (https:bacpac.chori.org) containing the Stoml3 gene was 1018 
isolated from RPCI-23 library17. A 12-kb DNA fragment containing the exon1 and its 1019 
flanking regions of Stoml3 gene was isolated by gap repair18. Homologous recombination in 1020 
bacteria 18,19 was used to fuse an NLS-lacZ cassette to the ATG of Stoml3 and to introduce 1021 
the self-excision neo cassette 20 into the Stoml3 locus. Similarly, homologous recombination 1022 
in bacteria was used to introduce a Strep-TagII after the ATG of Stoml3 and a neomycin 1023 
cassette flanked by two loxP into the first intron of Stoml3 locus to generate the Stoml3StrepII 1024 
allele. In both targeting vectors the MC1-diphteria toxin A (DTA) cassette was placed at the 1025 
3’ end of the vector and was used for negative selection. Colonies of the E14.1 ES cell line 1026 
(129/Ola) that had incorporated the targeting vector into their genome were selected by G418 1027 
and analyzed for homologous recombination by Southern blot analysis using 5’ and 3’ probes 1028 
that lie outside of the targeting vector. Two clones were microinjected into C57BL/6 1029 
blastocysts to generate chimeras that transmitted the Stoml3LacZ allele or the Stoml3StrepII 1030 
allele.  1031 
The Stoml3LacZ strain was genotyped using Stoml3-LacZ F: gac agt gtg atg tca ggg aag; LacZ 1032 
int R: cct tcc tgt agc cag ctt tca tc, Stoml3-LacZ R: cct tgt aaa ctg ata gcg ggg ac primers. The 1033 
Stoml3StrepII strain was genotyped using Stoml3-Strep F: gta gca gtg ttg ttt aga aag together 1034 
with Stoml3-StrepII R2 gct agc cat ggc tca ttc ttg for the mutant allele or with Stoml3-Strep 1035 
R1 aca gtg atg atg tcc cag c for the wild type allele.  1036 
 1037 
The Stoml3StrepII allele could conceivably negatively alter the function of the STOML3 1038 
protein. We thus generated homozygous Stoml3StrepII/StrepII mice and used the ex vivo skin 1039 
nerve preparation to determine if cutaneous mechanorecpetors lose mechanosensitivity in this 1040 
strain. Recordings from 4 wild type littermate controls and 4 Stoml3StrepII/StrepII mice revealed 1041 
no significant differences in the incidence of mechanoinsensitive fibers between the 1042 
genotypes. Amongst Aβ-fibers mechanoinsensitive fiber incidence was 1/21 (5%) and 0/23 1043 
(0%) for wild type and Stoml3StrepII/StrepII mice respectively Amongst Aδ-fibers 1044 
mechanoinsensitive fiber incidence was 0/12 (0%) and 1/11 (9%) for wild type and 1045 
Stoml3StrepII/StrepII mice, respectively.  1046 
 1047 
Histochemistry 1048 
Mice were perfused with ice-cold PBS followed by 0.5% gluteraldehyde for 20 minutes. 1049 
Post-fixed lumbar DRGs were washed several times in PBS and cryoprotected in 30% 1050 
sucrose overnight at 4°C. DRGs were embedded in O.C.T. Tissue-Tek (Sakura Finetek, 1051 
Netherland) on dry ice and stored at -80°C. Tissue was on a Cryostat CM3050S (Leica) and 1052 
slides were incubated in X-gal reaction buffer (35 mM potassium ferrocyanide, 35 mM 1053 
potassium ferricyanide, 2mM MgCl2, 0.02% Nonidet P-40, 0.01% Na deoxycholate and 1 1054 
mg/ml of X-Gal) for 2 days at 37°. Slices were washed several times in PBS until the solution 1055 
no longer turned yellow, air-dried and sealed with a coverslip.  1056 
Sections were observed on a Zeiss Axiovert 135 microscope using Zen imaging software 1057 
(Zeiss, Germany). Image J (NIH, USA) was used to manually trace the outlines of cell in 1058 
order to obtain cell area. Electron microscopy was performed on nerves using standard 1059 
methods as previously described7.  1060 
 1061 
Western blotting 1062 
 1063 
Tissues from Stoml3StrepII/StrepII and control mice were lysed with 8 M urea buffer and protein 1064 
concentration was determined using the Bradford reagent. Proteins were separated by SDS-1065 
PAGE, followed by Western blot analysis using mouse Strep-tagII antibody (2-1507-001, 1066 
IBA), PGP 9.5 antibody (ab10404, Abcam) and mouse anti β actin (A1978, Sigma). 1067 
Appropriate horseradish peroxidase-conjugated secondary antibodies were used for 1068 
chemiluminescence (ECL, Millipore or Supra, Thermo scientific SuperSignal). 1069 
 1070 
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